May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Intraocular Tissue Distribution of Betamethasone following an Intrascleral Implantation of Sustained Drug Delivery Device
Author Affiliations & Notes
  • K. Okabe
    Ophthalmology, Nagoya City University Medical school, Nagoya, Japan
  • H. Kimura
    Ophthalmology, Nagoya City University Medical school, Nagoya, Japan
  • J. Okabe
    Ophthalmology, Nagoya City University Medical school, Nagoya, Japan
  • A. Kato
    Ophthalmology, Nagoya City University Medical school, Nagoya, Japan
  • N. Kunou
    Ophthalmology, Nagoya City University Medical school, Nagoya, Japan
  • M. Nozaki
    Ophthalmology, Nagoya City University Medical school, Nagoya, Japan
  • Y. Ogura
    Ophthalmology, Nagoya City University Medical school, Nagoya, Japan
  • Footnotes
    Commercial Relationships  K. Okabe, None; H. Kimura, None; J. Okabe, None; A. Kato, None; N. Kunou, None; M. Nozaki, None; Y. Ogura, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4430. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Okabe, H. Kimura, J. Okabe, A. Kato, N. Kunou, M. Nozaki, Y. Ogura; Intraocular Tissue Distribution of Betamethasone following an Intrascleral Implantation of Sustained Drug Delivery Device . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4430.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To evaluate the tissue distribution of betamethasone (BM) after implantation of a non-biodegradable polymeric intrascleral implant as a new controlled intraocular delivery system. Methods: Intrascleral implants designed to release BM for at least 1 month were placed in the sclera of pigmented rabbits. The BM concentrations in the aqueous humor, vitreous, and retina/choroid were determined by high performance liquid chromatography (HPLC) at weeks 1, 2, and 4 after implantation. The BM concentrations in three sections of retina/choroid were also investigated. Retinal toxicity was evaluated by electroretinography and histological examination. Results: The BM release from the intrascleral implant in vitro and in vivo showed zero-ordered release profiles for 4 weeks. The BM concentrations in the retina/choroid after implantation of the intrascleral device remained higher than the effective concentrations for suppressing various inflammatory processes for at least 4 weeks. The BM concentrations in the retina/choroid around the implantation site were over 10 times higher than in the opposite side and the posterior pole throughout the study. No substantial toxic reactions were observed by electroretinography or histologic study. Conclusions: These findings suggested that the polymeric intrascleral implant could be a useful drug carrier for intraocular delivery of BM without producing severe retinal toxicity. The implantation site might be determined in consideration of the intraocular drug distribution after implantation.

Keywords: corticosteroids • retina • sclera 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×